$NKE

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

Original reporting
Published Aug 25, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Can These Beaten Down Stocks Bounce Back? — source image
Decision brief

The 30-second read

$NKEBearishLow
01

Why it matters

Both firms show mixed signals; earnings beats provide short‑term support, but revenue weakness and high valuations limit upside.

02

Market read

Earnings updates for two large‑cap stocks with recent underperformance; investors may reassess positions based on revenue trends.

03

What to watch

Nike's inventory management and ISRG's cost structure improvements could mitigate current headwinds.

Relevance 7/10Novelty 5/10Timing: post‑earnings analysis

Background

The article reviews recent earnings performance of two beaten‑down stocks, Nike and Intuitive Surgical, highlighting both positive earnings surprises and ongoing revenue challenges.

Company-level read

Ticker impact

$NKEBearishMedium confidence
Context

Nike reported Q4 adjusted EPS of $0.20 beating estimates but revenue fell 1% YoY to $11B, with direct sales down 7% and Greater China revenue down 17%.

Expected impact

Potential further downside or flat trading as investors weigh weak revenue against EPS beat.

Evidence & confidence

Revenue miss and soft direct sales outweigh EPS beat, likely limiting upside.

$ISRGNeutralMedium confidence
Context

Intuitive Surgical posted Q2 adjusted EPS of $2.80 (+27.9% YoY) beating estimates, revenue up 18.5% to $2.9B, but da Vinci procedure growth slowed and shares fell over 30% YTD.

Expected impact

Shares may stabilize with modest upside if growth picks up, but valuation compression limits rally.

Evidence & confidence

Earnings beat supports price, yet slowing growth and high multiples keep risk elevated.

Market effects

Both companies highlight challenges in consumer discretionary and healthcare equipment sectors amid valuation pressures.

Nike's China weakness may affect broader apparel exposure; ISRG's U.S. procedure slowdown signals caution for med‑tech.

Limited, confined to sector‑specific sentiment.

Counterpoint

Nike's turnaround could accelerate if digital initiatives improve; ISRG may benefit from long‑term surgical adoption despite short‑term slowdown.

Key entities

  • Nike, Inc.

    Apparel and footwear maker reporting Q4 results.

  • Intuitive Surgical, Inc.

    Medical device maker reporting Q2 results.

Related articles

$NKEMedAI 8/10

NIKE's Shares Fall More Than 2% Post Q1 Earnings: What's Ahead?

NIKE's shares dropped 2.2% after Q1 fiscal 2027 results showed a 4% revenue decline, despite an earnings beat. Greater China sales fell 22%, and the company expects fiscal 2027 revenues to decline at a high-single-digit rate. NIKE plans $2.5B in savings through fiscal 2031 but faces near-term sales pressure.